Trial Profile
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2018
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 20 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 Mar 2009 New trial record